Quifenadine
Clinical data | |
---|---|
Trade names | Fencarol |
Other names | 3-quinuclidinyldiphenylmethanol |
Routes of administration | Oral (tablets), IM |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 45% (Tmax = 1 hour)[1] |
Metabolism | Hepatic |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H23NO |
Molar mass | 293.40 g/mol g·mol−1 |
3D model (JSmol) | |
| |
|
Quifenadine (Russian: хифенадин, trade name: Phencarol, Фенкарол) is an 2nd generation antihistamine drug, marketed mainly in post-Soviet countries.[2][3] Chemically, it is a quinuclidine derivative.
Indications
- Allergic rhinitis
- Acute and chronic urticaria
- Angioedema
- Dermatitis
- Atopic dermatitis
- Pruritus[1]
References
- ^ a b "Fencarol (quifenadine) Tablets, for Oral Use. Full Prescribing Information". State Register of Medicines (in Russian). Retrieved 4 January 2016.
- ^ "Quifenadine". Drugs.com. Retrieved 28 January 2014.
- ^ Makarov, L.; Balykova, L.; Soldatova, O.; Komolyatova, V.; Serebruany, V. (2010). "The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: A randomized controlled pilot trial". American journal of therapeutics. 17 (4): 396–401. doi:10.1097/MJT.0b013e3181a86987. PMID 19487925.